Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era

First-line epoprostenol treatment may lead to greater improvement in exercise capacity than first-line bosentan. However, these greater exercise improvements did not translate into longer time to disease progression or survival.